Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 1, 2016, Pages 55-59

  Hauck, Lisa ^a   Bitzer, Michael ^a   Malek, Nisar ^a   Plentz, Ruben R ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

G2; Ki67; NET; survival; therapy

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; EVEROLIMUS; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; SOMATOSTATIN DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOREGUT; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; VERY ELDERLY; BLOOD; CLASSIFICATION; FACTUAL DATABASE; INTESTINAL NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOMARKERS, TUMOR; CHROMOGRANIN A; DATABASES, FACTUAL; FEMALE; HUMANS; INTESTINAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84944930338     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1064994     Document Type: Article

References (34)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.
2. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-10.
3. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010; 105: 2563-9.
4. Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121: 589-97.
5. OConnor JM, Marmissolle F, Bestani C, Pesce V, Belli S, Dominichini E, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol 2014; 2: 673-84.
6. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-64.
7. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008; 14: 5377-84.
8. Rinke A, Michl P, Gress T. Medical treatment of gastroenteropancreatic neuroendocrine tumors. Cancers 2012; 4: 113-29.
9. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-23.
10. Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol 2014; 15: 365-79.
11. Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, et al. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol 2014; 5: 7.
12. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: Radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol 2015; 172: R1-8.
13. van Vliet EI, Teunissen JJ, Kam BL, de Jong M, Krenning EP, Kwekkeboom DJ. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology 2013; 97: 74-85.
14. Rossi RE, Burroughs AK, Caplin ME. Liver transplantation for unresectable neuroendocrine tumor liver metastases. Ann Surg Oncol 2014; 21: 2398-405.
15. Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg 2011; 396: 299-311.
16. Strosberg JR. Systemic. treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. Endocr Pract 2014; 20: 167-75.
17. OToole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80: 79-84.
18. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13.
19. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-88.
20. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-23.
21. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963; 238-9.
22. Rindi G, Arnold R, Bosman F, Capella C, Klimstra D, Klöppel G, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In Bosman F, Carneiro F, Hruban R, Theise N.,. Editors WHO Classification of Tumours of the Digestive System. 4th edition. Lyon: International Agency for Research on Cancer; 2010. pp 13-14.
23. Jamali M, Runjan C. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 2008; 19: 282-8.
24. Scholzen T, Gerdes J. The Ki-67 Protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22.
25. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading and staging systems. Pancreas 2010; 39: 707-12.
26. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90: 162-6.
27. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-803.
28. Rindi G, DAdda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007; 18: 145-9.
29. Martin-Perez E, Capdevila J, Castellano D, Jimenez-Fonseca P, Salazar R, Beguiristain-Gomez A, et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology 2013; 98: 156-68.
30. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008; 14: 5377-84.
31. Eads JR, Meropol NJ. A new era for the systemic therapy of neuroendocrine tumors. Oncologist 2012; 17: 326-38.
32. Spitzweg C, Göke B. Therapy of endocrine gastrointestinal tumors. Internist (Berl) 2002; 43: 219-29.
33. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003; 39: 131-8.
34. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001; 91: 1992-2000.